Arcus Biosciences
Arcus Biosciences Inc is a clinical-stage biopharmaceutical enterprise headquartered in Hayward, California. The company specializes in the discovery and development of innovative therapies for cancer, with a pipeline focusing on small-molecule inhibitors and monoclonal antibodies targeting key tumor pathways. Its therapeutic candidates aim to modulate immune response and enhance efficacy in oncology indications. Principal revenue is currently earned through strategic pharmaceutical partnerships, licensing agreements, and capital financing arrangements as its drug candidates advance through clinical trials. Arcus Biosciences Inc is publicly listed on the New York Stock Exchange.
7 of the funds FundTelligence covers report a position in Arcus Biosciences.
- Legal name
- Arcus Biosciences Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
Funds holding Arcus Biosciences
- BNP US Small Cap — BNP Paribas · 1.01 % (full portfolio disclosed, June 2026)
- BNP Health Care Innovators — BNP Paribas · 0.72 % (full portfolio disclosed, June 2026)
- JPM Global Healthcare Fund — JPM · 0.33 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.16 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)